Intriguingly, whereas mutations in BRAF, NRAS and MEK1/2 usually occur in isolation within resistant tumours, non-MAPK alterations often co-exist with other genetic changes2, and this suggests that genetic and transcriptomic changes acquired during treatment failure may co-operate to select and promote resistance. The gene discussed is BRAF; the disease is neoplasm.